Physician profile
Merlyn A Johnson
NPI 1619104031
$4,034.66
in general payments reported to CMS, 2019-2025
30 companies · $519 in 2025
The $519 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,101 · 2020: $805 · 2021: $395 · 2022: $479 · 2023: $432 · 2024: $303 · 2025: $519.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,254.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $538.81 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $511.73 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $439.04 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $380.61 | 2022-2025 | Vraylar, Qulipta |
| Glaxosmithkline, LLC. | $370.47 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $301.41 | 2019-2021 | |
| Lilly USA, LLC | $296.40 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $203.25 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $158.76 | 2019-2023 | |
| Amgen INC. | $97.19 | 2019-2025 | Otezla, Repatha, Otezla |
| Astellas Pharma US INC | $94.02 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $85.22 | 2022-2025 | |
| Allergan, INC. | $60.39 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $59.86 | 2019-2020 | |
| Abbott Laboratories | $53.81 | 2022-2024 | Freestyle Libre 3 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $49.65 | 2020-2024 | Eliquis |
| Gilead Sciences, INC. | $46.52 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $40.94 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.20 | 2022-2024 | Xifaxan |
| Dexcom, INC. | $34.52 | 2024-2025 | Dexcom G6 Transmitter |
| Boston Scientific Corporation | $29.99 | 2019 | |
| Amarin Pharma, INC. | $29.08 | 2019-2021 | |
| Axsome Therapeutics, INC. | $19.21 | 2025 | Auvelity |
| Intuity Medical INC | $17.82 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Dynavax Technologies Corporation | $15.61 | 2022 | |
| Azurity Pharmaceuticals, INC. | $14.64 | 2023 | Horizant |
| Teva Pharmaceuticals USA, INC. | $13.69 | 2021 | |
| Clarus Therapeutics INC. | $12.66 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $11.78 | 2020 | |
| Sunovion Pharmaceuticals INC. | $11.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Merlyn Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.